Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-1) (NEAR-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04599933
Recruitment Status : Completed
First Posted : October 23, 2020
Last Update Posted : February 24, 2022
Sponsor:
Information provided by (Responsible Party):
Orasis Pharmaceuticals Ltd.

Brief Summary:
This is a 4-visit, multi-center, randomized, double-masked, vehicle-controlled study evaluating the safety and efficacy of CSF-1 in the temporary correction of presbyopia.

Condition or disease Intervention/treatment Phase
Presbyopia Drug: CSF-1 Drug: Vehicle Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 309 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multi-Center, Double-Masked, Vehicle-Controlled, Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (the NEAR-1 Study: Near Eye-vision Acuity Restoration)
Actual Study Start Date : October 19, 2020
Actual Primary Completion Date : February 11, 2022
Actual Study Completion Date : February 18, 2022

Arm Intervention/treatment
Experimental: CSF-1
One drop bilaterally twice daily for approximately 2 weeks.
Drug: CSF-1
One drop bilaterally twice daily for approximately 2 weeks.

Placebo Comparator: Vehicle
One drop bilaterally twice daily for approximately 2 weeks.
Drug: Vehicle
One drop bilaterally twice daily for approximately 2 weeks.




Primary Outcome Measures :
  1. Percentage of subjects with a ≥ 3-line gain in BDCVA (Best Distance-Corrected Visual Acuity) at 40cm and no loss in BDCVA ≥ 5 letters at 4m. [ Time Frame: Day 8 ]

Secondary Outcome Measures :
  1. Percentage of subjects with a ≥ 3-line gain in BDCVA at 40cm and no loss in BDCVA ≥ 5 letters at 4m. [ Time Frame: Day 1/Day 8/Day 15 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   45 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects must have presbyopia.

Exclusion Criteria:

Subjects must not:

  • Have any contraindications to the study medications or diagnoses that would confound the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04599933


Locations
Layout table for location information
United States, Arizona
Orasis Investigative Site
Sun City, Arizona, United States, 85351
United States, California
Orasis Investigative Site
Glendale, California, United States, 91204
Orasis Investigative Site
Los Angeles, California, United States, 90013
United States, Florida
Orasis Investigative Site
Fort Myers, Florida, United States, 33901
Orasis Investigative Site
Mount Dora, Florida, United States, 32757
United States, Georgia
Orasis Investigative Site
Morrow, Georgia, United States, 30260
United States, Kansas
Orasis Investigative Site
Overland Park, Kansas, United States, 66210
United States, Kentucky
Orasis Investigative Site
Louisville, Kentucky, United States, 40206
United States, Missouri
Orasis Investigative Site
Kansas City, Missouri, United States, 64133
Orasis Investigative Site
Saint Louis, Missouri, United States, 63131
United States, Nevada
Orasis Investigative Site
Henderson, Nevada, United States, 89052
United States, North Carolina
Orasis Investigative Site
Elizabeth City, North Carolina, United States, 27909
United States, Pennsylvania
Orasis Investigative Site
Cranberry Township, Pennsylvania, United States, 16066
Orasis Investigative Site
Wilkes-Barre, Pennsylvania, United States, 18702
United States, South Dakota
Orasis Investigative Site
Rapid City, South Dakota, United States, 57701
United States, Tennessee
Orasis Investigative Site
Memphis, Tennessee, United States, 38119
United States, Texas
Orasis Investigative Site
El Paso, Texas, United States, 79902
Sponsors and Collaborators
Orasis Pharmaceuticals Ltd.
Layout table for additonal information
Responsible Party: Orasis Pharmaceuticals Ltd.
ClinicalTrials.gov Identifier: NCT04599933    
Other Study ID Numbers: 20-150-0002
First Posted: October 23, 2020    Key Record Dates
Last Update Posted: February 24, 2022
Last Verified: October 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Presbyopia
Refractive Errors
Eye Diseases